Abstract. A century ago, Alfred Nissle discovered that intentional intake of particular strains of Escherichia coli could treat patients suffering from infectious diseases. Since then, one of these strains became the most frequently used probiotic E. coli in research and was applied to a variety of human conditions. Escherichia coli Nissle 1917 (EcN) is a non-pathogenic gram-negative bacterium belonging to the Enterobacteriaceae family . In contrast to other E. coli strains, this strain does not produce virulence factors and reduces colonic mucosal damage by stimulating the production of human beta-defensin 2, a crucial molecule that protects the mucosal Escherichia coli Nissle 1917 (EcN) is the active component of Mutaflor® (Ardeypharm GmbH, Herdecke, Germany), a probiotic drug licensed in several countries for the treatment of multiple The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol. 2004; 40 :223–229. This study investigated the ability of probiotic Escherichia coli Nissle 1917 (EcN) to outcompete the biofilm formation of pathogens including enterohemorrhagic E. coli (EHEC), Pseudomonas An update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety is proposed, and the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine is proposed. Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors Probiotics are viable non-pathogenic microorganisms that confer health benefits to the host by improving the microbial balance of the indigenous microflora. 9 Apart from anecdotal experience, two controlled studies with the probiotic bacterial strain Escherichia coli Nissle 1917 (EcN) in UC already exist. 10, 11 These trials showed no EcN is a non-pathogenic, gram-negative bacterial strain that has probiotic properties and can directly compete with the E. coli involved in CBP development. Credit: image_jungle/Getty Images dwgyPK.

escherichia coli nissle 1917 probiotic